论文部分内容阅读
现已证实,IL-2单独或LAK细胞联用刘某些癌症(如恶性黑素瘤或肾细胞癌)以及有转移癌的鼠有作用。根据大小鼠实验,LAK 细胞和IL-2的组合对疗效有明显的协同作用。单用IL-2治疗时,实际的抗瘤效果仅在其相当大剂量时才看到。给予IL-2可增加NK 活性,使NK 细胞数扩增,并诱发LAK 活性,但产生此效果所需的剂量实际上已接近中毒的水平。由于IL-2半衰期短,为了维持体内LAK 活性所需的IL-2水平,必须连续静脉内输注或皮下、肌肉注射IL-2,但皮下注
It has been confirmed that IL-2 alone or LAK cells are used in combination with certain cancers (such as malignant melanoma or renal cell carcinoma) and rats with metastatic cancer. According to large mouse experiments, the combination of LAK cells and IL-2 has a significant synergistic effect on efficacy. When treated with IL-2 alone, the actual anti-tumor effect was seen only at its considerable dose. The administration of IL-2 increases NK activity, amplifies the number of NK cells, and induces LAK activity, but the dose required to produce this effect is practically close to the level of intoxication. Due to the short half-life of IL-2, in order to maintain IL-2 levels required for LAK activity in vivo, continuous intravenous infusion or subcutaneous, intramuscular injection of IL-2 is required, but subcutaneous injection